A New Immunotherapy Combination for Advanced Liver Cancer
The FDA approved the combination of two checkpoint inhibitors for certain patients with hepatocellular carcinoma. The U.S. Food and Drug Administration (FDA) has approved tremelimumab (Imjudo) in combination with durvalumab (Imfinzi) for adult patients...
